key: cord-0774423-79yna07e
authors: Zhang, Bao-zhong; Hu, Ye-fan; Chen, Lin-lei; Tong, Yi-gang; Hu, Jing-chu; Cai, Jian-piao; Chan, Kwok-Hung; Dou, Ying; Deng, Jian; Gong, Hua-rui; Kuwentrai, Chaiyaporn; Li, Wenjun; Wang, Xiao-lei; Chu, Hin; Su, Cai-hui; Hung, Ivan Fan-Ngai; Cheung Yau, Thomas Chung; To, Kelvin Kai-Wang; Yuen, Kwok Yung; Huang, Jian-Dong
title: Mapping the Immunodominance Landscape of SARS-CoV-2 Spike Protein for the Design of Vaccines against COVID-19
date: 2020-04-27
journal: bioRxiv
DOI: 10.1101/2020.04.23.056853
sha: 37e61663999bea25aaeb373907925b1d9dba511b
doc_id: 774423
cord_uid: 79yna07e

The ongoing coronavirus disease 2019 (COVID-19) pandemic is a serious threat to global public health, and imposes severe burdens on the entire human society. The severe acute respiratory syndrome (SARS) coronavirus-2 (SARS-CoV-2) can cause severe respiratory illness and death. Currently, there are no specific antiviral drugs that can treat COVID-19. Several vaccines against SARS-CoV-2 are being actively developed by research groups around the world. The surface S (spike) protein and the highly expressed internal N (nucleocapsid) protein of SARS-CoV-2 are widely considered as promising candidates for vaccines. In order to guide the design of an effective vaccine, we need experimental data on these potential epitope candidates. In this study, we mapped the immunodominant (ID) sites of S protein using sera samples collected from recently discharged COVID-19 patients. The SARS-CoV-2 S protein-specific antibody levels in the sera of recovered COVID-19 patients were strongly correlated with the neutralising antibody titres. We used epitope mapping to determine the landscape of ID sites of S protein, which identified nine linearized B cell ID sites. Four out of the nine ID sites were found in the receptor-binding domain (RBD). Further analysis showed that these ID sites are potential high-affinity SARS-CoV-2 antibody binding sites. Peptides containing two out of the nine sites were tested as vaccine candidates against SARS-CoV-2 in a mouse model. We detected epitope-specific antibodies and SARS-CoV-2-neutralising activity in the immunised mice. This study for the first time provides human serological data for the design of vaccines against COVID-19.

The coronavirus disease 2019 (COVID-19), a novel infectious disease caused by 48 severe acute respiratory syndrome coronavirus 2, SARS-CoV-2, first emerged in 49 December 2019 and has since become a worldwide pandemic. COVID-19 infections 50 have so far led to over 2 million cases and more than 0.13 million deaths across more Although a putative epitope that binds to antibodies against SARS-CoV-2 has been 76 reported 15 , more epitopes with high affinity need to be identified. Information on 77 these epitopes would be useful, particularly in regard to human immunological bias 78 4 and immunodominance (ID), which might restrict the immune response. 79 Immunodominance is the phenomenon of immunogenic variation among distinct 80 immunogens or antigenic sites on the same immunogen, which has been demonstrated 81 in both CD8 + T cells and B cells 16 . This phenomenon has restricted the development 82 of effective vaccines for influenza A and other highly variable viruses [17] [18] [19] . All the 83 methods used to overcome or manipulate these viral immunity restrictions rely on the 84 landscape of immunodominance. It is therefore crucial to map the immunogenicity 85 landscape of the potential epitopes of the S protein to accelerate the development of identified five linear immunodominant (ID) sites in the S protein that did not induce 92 neutralising antibodies. On the contrary, the RBD was found to contain the major 93 neutralising epitopes in the S protein, but did not have any ID sites 21 .

In this study, we aimed to map the landscape of ID sites within the S protein of 95 SARS-CoV-2 and compare these results with those of its counterpart in SARS-CoV.

Unlike SARS-CoV, we found the RBD of SARS-CoV-2 had linear ID sites in sera 97 samples collected from recently discharged COVID-19 patients. Subsequent 98 microneutralisation tests demonstrated that mice immunised with peptides containing 99 the ID sites within RBD produced neutralising antibodies. Taken together, the RBD of 100 SARS-CoV-2 has a different ID landscape to its counterpart in SARS-CoV.

Furthermore, these data can provide guidance on the design of S protein-based SARS-

CoV-2 vaccines that might avoid adverse reactions or disease-enhancing effects. as secondary infections that need to be considered. 284 We also analysed the correlation between S or N protein-specific antibody levels and tested if the ID sites in the RBD fragment could be used as potential vaccines in mice. 298 We found that epitopes/protein-specific antibody titres exceeded the 299 microneutralisation titres by several orders of magnitude. Considering the relatively 300 low neutralising antibody levels in the recovered patients in this study and in a 301 previous report 26 , it is reasonable to expect significant differences between specific 302 antibodies and neutralising antibodies. We found there was equivalent antiviral 303 activity from immunisation with epitopes compared to immunisation with the entire 304 13 RBD fragment (Figure 4 ). This provides evidence that epitope-based vaccines could 305 offer comparable protection compared to subunit vaccines, but with the potentially 306 better safety. 307 We also compared binding residues of previously identified SARS-CoV-2 308 neutralising antibodies with ID epitopes. The ID sites in the RBD were found to be histopathological changes 30 . Even so, these results provide limited information on ID. 318 We still do not know how to effectively target immunodominance, and we still need 319 to understand the mechanism underlying this phenomenon. 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 

WHO launches global megatrial of the four most 350 promising coronavirus treatments

A new coronavirus associated with human respiratory disease in 352

Genomic characterisation and epidemiology of 2019 novel 354 coronavirus: implications for virus origins and receptor binding

A pneumonia outbreak associated with a new coronavirus of 357 probable bat origin

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 359 and is blocked by a clinically proven protease inhibitor

Structural basis for the recognition of SARS-CoV-2 by full-length 361 human ACE2

Cryo-EM structure of the 2019-nCoV spike in the prefusion 363 conformation

The COVID-19 vaccine development landscape

A Sequence Homology and Bioinformatic Approach Can Predict 367

Candidate Targets for Immune Responses to SARS-CoV-2

Preliminary identification of potential 370 vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-371

Development of epitope-based peptide vaccine against 373 novel coronavirus 2019 (SARS-COV-2): Immunoinformatics approach

Novel antibody epitopes dominate the antigenicity of 376 spike glycoprotein in SARS-CoV-2 compared to SARS-CoV

Potential T-cell and B-cell Epitopes of 2019-nCoV

Epitopes for a 2019-nCoV vaccine

A highly conserved cryptic epitope in the receptor-binding 383 domains of SARS-CoV-2 and SARS-CoV

Understanding and manipulating viral immunity: 385 antibody immunodominance enters center stage

Quantifying the shifting landscape of B cell 388 immunodominance

Defining B cell immunodominance to viruses

Slow delivery immunization enhances HIV neutralizing 392 antibody and germinal center responses via modulation of immunodominance